Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2025.0185 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Elizabeth M Swisher und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle. Hauptthemen laut MEDLINE: Primary Health Care, Genetic Testing, Early Detection of Cancer, Genetic Predisposition to Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Importance Best practices for improving access to assessment of hereditary cancer risk in primary care are lacking.
Objective
To compare 2 population-based engagement strategies for identifying primary care patients with a family or personal history of cancer and offering eligible individuals genetic testing for cancer susceptibility. Design, Setting, and Participants The EDGE (Early Detection of Genetic Risk) clinical trial cluster-randomized 12 clinics from 2 health care systems in Montana, Wyoming, and Washington state to 1 of 2 engagement approaches for assessment of hereditary cancer risk in primary care. The study population included 95 623 English-speaking patients at least 25 years old with a primary care visit during the recruitment window between April 1, 2021, and March 31, 2022.
Intervention
The intervention comprised 2 risk assessment engagement approaches: (1) point of care (POC), conducted by staff immediately preceding clinical appointments, and (2) direct patient engagement (DPE), where letter and email outreach facilitated at-home completion. Patients who completed risk assessment and met prespecified criteria were offered genetic testing via a home-delivered saliva testing kit at no cost. Main Outcomes and Measures Primary outcomes were the proportion of patients with a visit who (1) completed the risk assessment and (2) completed genetic testing. Logistic regression models were used to compare the POC and DPE approaches, allowing for overdispersion and including clinic as a design factor. An intention-to-treat analysis was used to evaluate primary outcomes.
Results
Over a 12-month window, 95 623 patients had a primary care visit across the 12 clinics. Those who completed the risk assessment (n = 13 705) were predominately female (64.7%) and aged between 65 and 84 years (39.6%). The POC approach resulted in a higher proportion of patients completing risk assessment than the DPE approach (19.1% vs 8.7%; adjusted odds ratio [AOR], 2.68; 95% CI, 1.72-4.17; P < .001) but a similar proportion completing testing (1.5% vs 1.6%; AOR, 0.96; 95% CI, 0.64-1.46; P = .86). Among those eligible for testing, POC test completion was approximately half of that for the DPE approach (24.7% vs 44.7%; AOR, 0.49; 95% CI, 0.37-0.64; P < .001). The proportion of tested patients identified with an actionable pathogenic variant was significantly lower for the POC approach than the DPE approach (3.8% vs 6.6%; AOR, 0.61; 95% CI, 0.44-0.85; P = .003). Conclusions and Relevance In this cluster randomized clinical trial of risk assessment delivery, POC engagement resulted in a higher rate of assessment of hereditary cancer risk than the DPE approach but a similar rate of genetic testing completion. Using a combination of engagement strategies may be the optimal approach for greater reach and impact. Trial Registration ClinicalTrials.gov Identifier: NCT04746794
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle.
- Department of Bioethics and Humanities, School of Medicine, University of Washington, Seattle.
- Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle.
- Institute for Public Health Genetics, School of Public Health, University of Washington, Seattle.
- Collaborative Science and Innovation, Billings Clinic, Billings, Montana.
- Clinical Science & Innovation Department, City of Hope, Duarte, California.
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Swisher, E. M., Harris, H. M., Knerr, S., Theoryn, T. N., Norquist, B. M., Brant, J., Shirts, B. H., Beers, F., Cameron, D., Dusic, E. J., Riemann, L. A., Devine, B., Raff, M. L., Kadel, R., Cabral, H. J., & Wang, C. (2025). Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.0185
Vancouver
Swisher EM, Harris HM, Knerr S, Theoryn TN, Norquist BM, Brant J, et al. Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.0185
BibTeX
@article{Swisher2025,
author = {Swisher, Elizabeth M and Harris, Heather M and Knerr, Sarah and Theoryn, Tesla N and Norquist, Barbara M and Brant, Jeannine and Shirts, Brian H and Beers, Faith and Cameron, DaLaina and Dusic, Emerson J and Riemann, Laurie A and Devine, Beth and Raff, Michael L and Kadel, Rabindra and Cabral, Howard J and Wang, Catharine},
title = {Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2025.0185}
}
EUVIMED